Tesamorelin

What is Tesamorelin?

Tesamorelin is an FDA-approved synthetic GHRH analog marketed as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is one of the few growth hormone-related peptides to achieve FDA approval.

Tesamorelin is a modified form of human GHRH (1-44) with a trans-3-hexenoic acid group attached, which provides improved stability and pharmacokinetic properties.

FDA-Approved Use

Egrifta (Tesamorelin)

Approved for:

• HIV-associated lipodystrophy
• Reduction of excess abdominal fat
• Daily subcutaneous injection (2 mg)

Key Clinical Trial Results

• Significant reduction in trunk fat
• Improvements in lipid profiles
• Maintained over extended treatment
• No significant effect on limb fat

Molecular Profile

Structure

Modified GHRH (1-44) with:

• Trans-3-hexenoic acid modification
• Enhanced stability
• 44 amino acids

Molecular Data

Mechanism of Action

GHRH Receptor Activation

• Stimulates pituitary GH release
• Increases IGF-1 levels
• Promotes lipolysis
• Reduces visceral adipose tissue

Effects on Body Composition

• Reduces trunk/visceral fat
• Improves waist circumference
• Effects specific to central adiposity
• Minimal effect on subcutaneous fat

Comparison with Other GHRH Analogs

Side Effects

Common:

• Injection site reactions
• Joint pain (arthralgia)
• Swelling in extremities
• Muscle pain

Considerations:

• May affect glucose metabolism
• Not for general weight loss
• Specific to HIV lipodystrophy indication

Summary

Tesamorelin stands out as one of few GH-related peptides with FDA approval, specifically for the underserved population with HIV lipodystrophy.

Key Points:

• Classification: GHRH analog
• Brand: Egrifta
• FDA Status: Approved for HIV lipodystrophy
• Mechanism: Stimulates natural GH release